ACAD 250516 14.00C(ACAD250516C14000) Stock Price Today

3.20
+1.83+133.58%

15min DelayClose May 8 16:00 ET

3.27High2.06Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

74425369

Mar 12 23:06

How Inflation Silently Erodes Company Valuations

When inflation rises, investors often focus on obvious impacts like higher consumer prices or interest rates. However, a more profound transformation occurs beneath the market's surface—one that fundamentally reshapes how companies are valued. Understanding this mechanism gives investors crucial insight into why certain stocks plummet while others remain resilient during inflationary periods.
The market's recent behavior tells a compelling story. A...

CPI data falls short of expectations: Is a market recovery in sight?

Jaguar8

Mar 5 22:15

NEWS

$ACADIA Pharmaceuticals (ACAD.US)$
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med
Acadia Pharmaceuticals (NASDAQ: ACAD) announced the publication of clinical data from the open-label DAFFODIL™ study in the journal Med, evaluating DAYBUE® (trofinetide) in Rett syndrome patients. The Phase 2/3 study focused on children aged 2-4 years (n=15) and demonstrated safety profiles consistent with previou...

Trytosaveabit

Mar 5 22:13

Update

$ACADIA Pharmaceuticals (ACAD.US)$ Acadia Pharmaceuticals Announces DAYBUE Study Results In Med Journal; Open-Label DAFFODIL Study Shows Comparable Safety For Rett Syndrome in 2-4 Age Group; Results Support FDA Approval for Ages 2+
Benzinga· 5 mins ago
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the journal Medpublished results from the open-label study, DAFFODIL, evaluating the safety, tolerability and exploratory efficacy of DAYBUE (trofinetide) in girls ages two to fou...

Teddy123

Mar 5 22:11

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

$ACADIA Pharmaceuticals (ACAD.US)$
Can Acadia's Rett Syndrome Treatment Change Patient Lives? New Clinical Data Reveals Key Insights

Jaguar8

Jan 14 22:06

NEWS

$ACADIA Pharmaceuticals (ACAD.US)$
Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome
6 minutes ago, 6:00 AM PST
Via BusinessWire
ACAD
Share
-- Filing marks company's first Marketing Authorization Application in Europe
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tr...

ACAD250516C14000

News

Comments